Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2

Item Type:Article
Title:The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
Creators Name:Lakhani, S.R. and Van de Vijver, M.J. and Jacquemier, J. and Anderson, T.J. and Osin, P.P. and McGuffog, L. and Easton, D.F. and Scherneck, S. and Seitz, S.
Abstract:PURPOSE: The morphologic and molecular phenotype of breast cancers may help identify patients who are likely to carry germline mutations in BRCA1 and BRCA2. This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes. MATERIALS AND METHODS: Samples of breast cancers obtained from the International Breast Cancer Linkage Consortium were characterized morphologically and immunohistochemically using antibodies to estrogen receptor, progesterone receptor, HER-2 (c-erbB-2 oncogene), and p53 protein. RESULTS: Breast cancers in patients with BRCA1 germline mutations are more often negative for estrogen receptor, progesterone receptor, and HER-2, and are more likely to be positive for p53 protein compared with controls. In contrast, BRCA2 tumors do not show a significant difference in the expression of any of these proteins compared with controls. CONCLUSION: BRCA1 has a distinctive morphology and immunohistochemical phenotype. The combined morphologic and immunohistochemical data can be used to predict the risk of a young patient harboring a germline mutation in BRCA1. The BRCA2 phenotype is currently not well defined.
Keywords:Breast Neoplasms, Chi-Square Distribution, BRCA1 Genes, BRCA2 Genes, Germ-Line Mutation, Immunoenzyme Techniques, Immunophenotyping, Logistic Models, Predictive Value of Tests, erbB-2 Receptor, Estrogen Receptors, Progesterone Receptors, Tumor Suppressor Protein p53
Source:Journal of Clinical Oncology
ISSN:0732-183X
Publisher:American Society for Clinical Oncology (U.S.A.)
Volume:20
Number:9
Page Range:2310-2318
Date:1 May 2002
Official Publication:http://jco.ascopubs.org/cgi/content/abstract/20/9/2310
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library